Myeloid cell leukemia 1 (Mcl-1) is an antiapoptotic member of the Bcl-2 family of proteins that when overexpressed is associated with high tumor grade, poor survival, and resistance to chemotherapy. Mcl-1 is amplified in many human cancers, and knockdown of Mcl-1 using RNAi can lead to apoptosis. Thus, Mcl-1 is a promising cancer target. Here, we describe the discovery of picomolar Mcl-1 inhibitors that cause caspase activation, mitochondrial depolarization, and selective growth inhibition. These compounds represent valuable tools to study the role of Mcl-1 in cancer and serve as useful starting points for the discovery of clinically useful Mcl-1 inhibitors.
The Bcl-2 family of proteins regulates apoptosis, a process of programmed cell death used to eliminate unwanted cells such as cancer cells [1] [2] [3] [4] . Abnormal cells can dysregulate this process to avoid cell death [1, 2] . One of the ways that cancer cells can accomplish this is by upregulating the antiapoptotic members of the Bcl-2 family of proteins [1, 5, 6] . Indeed, amplification of the gene encoding the antiapoptotic Bcl-2 family protein myeloid cell leukemia-1 (Mcl-1) is one of the most common genetic aberrations in human cancer [7] , and Mcl-1 overexpression in human cancers is associated with high tumor grade and poor survival [8] [9] [10] . In addition, Mcl-1 activity has also been implicated in the resistance to multiple Abbreviations Bad, Bcl-2-associated death promoter; Bak, Bcl-2 homologous antagonist killer; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; Bcl-xL, B-cell lymphoma extra large; BH3, Bcl-2 homology domain 3; Bim, Bcl-2-interacting mediator of cell death; FITC, fluorescein isothiocyanate; FPA, fluorescence polarization anisotropy; Mcl-1, myeloid cell leukemia 1; Noxa, PMAIP1 gene Phorbol-12-myristate-13-acetateinduced protein 1. therapies, including paclitaxol, and venetoclax which are prescribed for cancer patients [8, 11] . Targeted inhibition of Mcl-1 has been demonstrated to cause tumor cell death in Mcl-1-dependent cancers and to increase the sensitivity of many standard chemotherapeutics in cancers that have developed resistance to the normal apoptotic process [12, 13] . Thus, Mcl-1 represents a promising target for cancer drug discovery. However, Mcl-1 mediates its effects through protein-protein interactions [14] and is considered difficult to target with small molecules. Nevertheless, progress has been made toward this goal. Several groups have reported Mcl-1 inhibitors that have a range of binding affinities and activity in cell-based assays including, UM-36 (University of Michigan) [15] , EU5346 (Eutropics Incorporated, Cambridge, MA, USA) [16] , Patent EP2886545A1 (Servier Research Institute of Medicinal Chemistry, Budapest, Hungary/Vernalis (R&D) Ltd., Cambridge, UK), Patent WO2016033486 (Amgen, Thousand Oaks, CA, USA), AZ-Mcl1 (Astra Zeneca, Waltham, MA, USA) [17] , Dual Mcl-1/Bcl-xl inhibitors (Takeda, Cambridge, MA, USA) [18] , and the AbbVie inhibitor, A-1210477 [19, 20] . We have also reported on the discovery of small molecules that bind to Mcl-1 with high affinity that were discovered using fragment-based screening and structure-based design [21, 22] . Here, we describe how these compounds were further optimized to obtain Mcl-1 inhibitors that display picomolar binding affinities and on-target mechanism-based activity in cells. We also show that these compounds have activity in primary cancer patient-derived cell lines.
Methods

Chemistry
Synthesis protocols and compound characterization have been reported in the Supporting information. The indole amides (2-5) were described in detail in publication No. WO/2015/148854 titled 'SUBSTITUTED INDOLE MCL-1 INHIBITORS.' All samples were of ≥ 95% purity as analyzed by LCÀUV/vis-MS. All reagents were purchased from chemical suppliers and used without purification.
Protein expression and purification for assays and X-ray structures
Protein preparation was described previously [21] . Briefly, a previously reported [23] construct was subcloned into an expression vector (pDEST-HisMBP) expressed in Escherichia coli BL21 CodonPlus (DE3) RIL (Stratagene, San Diego, CA, USA) and purified through nickel-column and size-exclusion chromatography sequentially.
Protein crystallization, data collection, and structure refinement Structural studies were performed as previously described [21] . Briefly, Mcl-1 protein (15 mgÁmL À1 ) was mixed with a 1.29 excess of ligand in solution (25-30% PEG 3350, 0.1 M Bis-Tris pH 6.5, 0.2 M MgCl 2 ) by hanging drop followed by flash freezing after cryo-protection using 10-20% glycol. Data were collected at Life Sciences Collaborative Access Team (LS-CAT) 21-ID-G beamline, Advanced Photon Source, Argonne National Laboratory. Indexing, integration, and scaling were performed with HKL2000 (HKL Research, Chalottesville, VA, USA) [23] , phasing by molecular replacement with Phaser (CCP4) [24, 25] using the structure (PDB: 4HW2) as a model, refinement used Phenix [26] . Structural statistics are given in the Supporting information. Figures were prepared with PyMOL (Schrödinger, LLC: New York, 2010) [27] .
Competition binding assays
A FITC-labeled BH3 peptide derived from Bcl-2-interacting mediator of cell death (Bim) (FITC-Bim; FITC-AHx-EARIAQELRRIGDEFNETYTR-NH2) or Bak (FITCBak; FITC-AHx-GQVGRQLAIIGDDINR-NH2) were purchased (Genscript, Piscataway, NJ, USA). Fluorescence polarization anisotropy (FPA) measurements used 384-well, black, flat-bottom plates (Greiner Bio-One, Kremsmunster, Austria) and a BioTek Cytation 3. FITCBim assay conditions: 20 mM Tris pH 7.5, 50 mM NaCl, 3 mM DTT, 0.01% CHAPS, FITC-Bim peptide at 1 nM, and His6-MBP Mcl-1 at 1.5 nM. Bcl-xl or Bcl-2 assay conditions: 10 nM FITC-Bak peptide incubated with either 15 nM Mcl-1, 4 nM Bcl-xL, or 4 nM Bcl-2 in 20 mM Tris pH 7.5, 50 mM NaCl, 3 mM DTT, and 5% final DMSO. Fetal calf serum (1%) is added in 1% FBS assay. Compounds were diluted in DMSO, (10-point, threefold serial dilutions) added to assay plates, and incubated for 0.5 h at room temperature. The TR-FRET assay used the assay buffer described above plus 300 nM FITC-BAK, 1 nM Mcl-1-MBP fusion, 1 nM MBP-terbium (Cisbio, Bedford, MA, USA), and 0.05% Pluronic F-68 (Sigma-Aldrich, St. Louis, MO, USA). Mixtures were incubated for 3 h and signal (Delta F) was measured on the Biotek Cytation 3 equipped with a filter cube containing an Ex 340/30 nM Em 620/10 filter and an Ex 340/30 Em 520 filter.
IC 50 values were calculated by fitting anisotropy using XLFit (IDBS) and converted into a binding dissociation constant [28] to give K i . Two or more repeats were obtained and average K i values are reported.
JC1 BH3 profiling and intracellular BH3 (iBH3) profiling
Synthetic peptides for MS-1 [29] (ac-RPEIWMTQGLR RLGDEINAYYAR-NH 2 ), Bim-BH3 (ac-MRPEIWIAQE LRRIGDEFNA-NH 2 ), HRK (Ac-WSSAAQLTAARLKA LGDELHQ-NH2), and Bad-BH3 (ac-LWAAQRYGREL RRMSDEFEGSFKGL-NH 2) were purchased (Genscript). JC1 BH3 profiling for Fig. 4A ,B was performed as described previously [30] . For Fig. 4C cytochrome c loss was measured by iBH3 profiling as described earlier [11] . Following cell fixation and cell quenching, cells were stained with of 1 : 100 dilution of anti-cytochrome cAlexa647 (clone 6H2.B4; #612310; BioLegend, San Diego, CA, USA) in a 109 staining buffer (20% FBS, 10% BSA, 1% Saponin, 3 mM Sodium Azide in PBS) to measure cytochrome c loss. Cytochrome c retention was measured on BD LSRII after overnight incubation with antibody and cytochrome c retention was measured using the following equation:
Cytochrome c loss ¼ 100Àð% of cells within cytochrome c retention gateÞ
Cell line proliferation assay
Cells were dispensed into 96-well plates at a concentration of 1000 cells per well in RPMI supplemented with 10% FBS and 0.05 mM 2-Mercaptoethanol and incubated overnight at 37°C in a tissue culture incubator. Compounds were diluted in DMSO (0.5%) and added to the cells. Plates were incubated for 72 h, and cell viability was measured using the Cell TiterGlo reagent. % Viability was defined as relative luminescence units RLU of each well divided by the RLU of cells on day 0. Dose-response curves were generated, and GI 50 values were determined using XLFIT (IDBS, Guildford, UK) software.
Caspase activation assay
Cells were dispensed in 96-well plates as described in the proliferation assay methods with 5% FBS and a cell concentration of 5000 cells per well. 
Generation of engineered cell lines
As described previously [31] human BCL-XL, BCL-W, BCL-2 and BFL-1 cDNAs, and a BCR-ABL (p185) oncofusion plasmid were stably expressed in Mcl-1 conditional Arf-deficient bone marrow by retroviral transduction and puromycin selection (2 lgÁmL À1 ; Sigma-Aldrich). Endogenous murine Mcl-1 was deleted by transduction with Cre recombinase.
Cell death experiments in engineered cell lines
The BCR-ABL p185 + B-ALL cell lines reprogrammed with human anti-apoptotic BCL-2 family members were seeded in 96-well round bottom plates (6 9 10 4 cells/ well). Mcl-1 inhibitors were solubilized in DMSO or DMSO vehicle controls were added at the indicated concentrations, and cells were in complete RPMI media with 1% FBS. After 24 h, the plates were centrifuged and cell viability was determined by staining with Annexin-V-APC and propidium iodide (BD Biosciences, San Jose, CA, USA) and measured by flow cytometry using the high-throughput sampler on a FACSCanto II (BD Biosciences).
protocol from consenting myeloma patients and prepared as described earlier [32] . Briefly, aspirates were diluted to 20 mL with PBS, and underlaid with lymphocyte separation medium (Media Tech/Corning Life Sciences, Tewksbury, MA, USA). The buffy coat was washed, resuspended in culture medium, and stained with anti-CD38-phycoerythrin, anti-CD45-allophycocyanin-Cy7, and anti-CD138-fluorescein isothiocyanate antibodies (BD Biosciences) for FACS analysis. Plasma cells were prepared for purification using MACS Cell Separation MS Columns and CD138 magnetic microbeads as per the manufacturer's protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). Once isolated, CD138-positive cells were checked for purity via flow cytometry. Cells (0.25 9 10 6 cellsÁmL À1 ) were treated with the indicated concentrations of compound 5 for 24 h and apoptosis determined by staining with anti-CD38-phycoerythrin and anti-CD45-allophycocyanin-Cy7 antibodies and Annexin-V-fluorescein isothiocyanate; three million cells were used for coimmuoprecipitation analysis.
Immunoprecipitation experiments on myeloma cells were performed using the Exacta-Cruz TM C Kit (Santa Cruz Biotechnology, Inc.) following the manufacturer's instructions as previously described [32] . The following primary antibodies were used: mouse anti-Mcl-1 mAb (BD Biosciences); hamster anti-Bcl-2 mAb (BD Biosciences); mouse anti-Bcl-x L mAb (7B2.5 [32] ). The resulting complexes were analyzed by western blotting using a rabbit anti-Bim pAb (EMD Millipore, Temecula, CA, USA). The secondary antibody was provided in the Exacta-Cruz TM C Kit (Santa Cruz Biotechnology, Inc.).
Proliferation of AML patient samples
Bone marrow aspirates were collected following a Vanderbilt University Institutional Review Board-approved protocol from consenting acute myeloid leukemia (AML) patients. Bone marrow aspirates in acid citrate dextrose tubes were added to ACK lysis buffer at room temperature for 5 minutes. Samples were then diluted with 20-40 mL of PBS, and centrifuged at 200 g for 10 min. Supernatant was discarded, and cell pellet was resuspended in 5 mL of PBS. Cells were dispensed into 96-well plates at a concentration of 6000 cells per well in RPMI supplemented with 10% FBS. Compound was diluted in DMSO and added to the cells at the given concentrations with a final DMSO concentration of 0.03%. Compound-treated plates were incubated at 37°C for 24 h. Cell viability was measured using the Cell TiterGlo reagent (Promega), and the relative luminescence units (RLU) were measured. Viability was defined as RLU of each well divided by the RLU of cells treated with DMSO vehicle. Dose-response curves were generated using PRISM (GraphPad, La Jolla, CA, USA) software.
Results and Discussion
Discovery of Mcl-1 inhibitors
The progression of our previously reported lead compound to our picomolar Mcl-1 inhibitors (4, 5) that possess mechanism-based activities in cells is summarized in Fig. 1 . Compound 1 was discovered by merging together two hits obtained in a fragment-based screen followed by further potency optimization using structure-based design [21] . This compound displaced a fluorescently labeled peptide derived from the proapoptotic protein Bak with a K i of 55 nM. However, this was not potent enough to elicit cellular activity. The necessity of picomolar-binding affinity to exhibit robust activity in cells is consistent with previously reported inhibitors for other Bcl-2 family members [20, 33] . Another problem with compound 1 is it showed reduced binding to Mcl-1 in the presence of serum, suggesting that it binds tightly to serum proteins. Anionic lipophilic compounds like 1 generally bind tightly to albumin [34, 35] . Compounds that bind to plasma proteins have less free fraction available to interact with cells in the in vitro cell assay and we and others have found that adding FBS to the biochemical binding assay is a useful way to gauge progress on reducing plasma binding.
To further improve the affinity of 1 to Mcl-1, we screened substituted aromatic heterocyclic groups at the 7-position of the indole and found that various methyl pyridines, 3,5 di-methyl oxazoles as well as the 1,3,5-tri-methyl-4-pyrazolo group improved affinity while maintaining desirable pharmaceutical properties. A similar approach was also employed by the AbbVie group [19] . However, the resulting indole acid was not able to show convincing activity in the Mcl-1-sensitive cell line (NCI H929).
The X-ray cocrystal structure of 1 complexed to Mcl-1 ( Fig. 2A) revealed the key charge-charge interactions between the carboxylate of 1 and guanidinium of R263, which was crucial for binding. This analysis led us to consider the expansion of an inhibitor beyond the P2 pocket first using a sulfonamide [36] and then an amide linkage in which the carbonyl moiety could maintain the favorable hydrogen bond with R263.
Through extensive SAR studies, compound 2 containing the 3-benzoic acid amide was discovered. Initially, the amide series of our compounds suffered from a considerable loss in affinity when the anionic carboxylate was replaced with the neutral amide group. However, introduction of a suitable aromatic acid through an amide linkage fully recovered the affinity loss by creating new binding interactions. It is also noteworthy that compound 2 showed almost 20-fold higher potency than the parent indole acid 1 in the presence of 1% FBS despite their comparable binding affinities without serum (Table 1) . These results suggested that the 2-indole amide inhibitor series offered a new opportunity with greater expandability and could have significantly lower nonspecific serum protein binding than the 2-indole acids.
To understand the binding interactions for further optimization, we obtained an X-ray structure of 2 complexed with Mcl-1. When the crystal structure of 2 is superimposed with 1 ( Fig. 2A) , we find that the indole cores of both molecules superimpose and that the carbonyl of compound 2 maintains polar interactions with R263. The crystal structure contains four copies of the Mcl-1 protein in an asymmetric unit, and two equally populated 3-benzoic acid conformations of 2 (Fig. 2B) . In both conformations, the phenyl group sits over the guanidinium moiety of R263 in a large hydrophobic shelf formed by the loop and the top of helix 4 and 5 of the protein to form a cation-p stacking which likely enhances the stability of the complex [37] . However, the carboxylate moiety in each conformation utilizes different polar contacts in the perimeter of the shelf. In the first pose (cyan) (Fig. 2A,B) , the carboxylate is positioned above the guanidinium of R263 to engage in a favorable charge-charge interaction. In contrast, the group is flipped to form a Hbond with the side chain of N260 in the second pose of compound 2 (olive Fig. 2B ). In both cases, these newly introduced binding interactions involving the 3-benzoic acid group are important for binding and overcoming the large loss in affinity to Mcl-1 when the carboxylate that was directly attached to the indole core of 1 was removed.
Inspection of the Mcl-1 bound conformation of 2 ( Fig. 2C ) also indicated a near planar arrangement of the amide and indole. Furthermore, the NH's of both groups point in the same direction, which is ideal for tethering. Based on the X-ray structure, these two atoms were bridged to form a tricyclic indole lactam 3 to lock the binding conformation. This modification resulted in multiple benefits for the series by optimizing both potency and the pharmaceutical properties of the compounds [38, 39] . As shown in Table 1 , the indole lactam 3 exhibited > 10 fold enhanced binding affinity when compared to the open chain analog 2. Also, by removing two rotatable bonds and two H-bond donors, this significantly improved passive permeability as assessed by a parallel artificial membrane permeability assay (PAMPA). This change also reduced the interference from serum in our binding assay to a single-digit nanomolar K i and improved the compound's aqueous solubility. Finally, it is possible that our tethering strategy enhances oral bioavailability [40] by effectively eliminating a secondary peptide bond that would be vulnerable to proteolysis in the GI tract. The structure of 2 (Fig. 2B ) also suggested that the benzoic acid head group only accesses a small portion of the hydrophobic shelf. This suggests that a larger fused bicyclic aromatic ring may be better suited to bind to this site. To test this hypothesis, compounds 4 and 5 were synthesized using an indole. In both compounds, the structural motif of the 3-benzoate of 2 was preserved to capture all of the favorable interactions while the fused methyl-pyrrole portion was introduced with different trajectories. When tested, both compounds had significantly higher potency than 3 by exhibiting picomolar binding affinities to Mcl-1, which was below the level able to be accurately determined in our FPA assay conditions. They also maintained low nanomolar K i 's in the presence of 1% FBS.
To understand the gains in potency, we obtained a structure of compound 5 in complex with Mcl-1 and found only one conformation for the indole acid of 5. As shown in Fig. 2D , the meta-benzoate portion of indole adopts the same binding pose as the first conformation of 2 (cyan) to preserve all of the desirable binding attributes. The methyl-pyrrazole moiety is extended toward N260 to cover a wider area of the hydrophobic binding interface over the propylene chain of R263 which likely contributes to its improved binding affinity. The contacts of the indole acid headpiece, as shown in the high-resolution X-ray structure, contributes significantly to affinity which is consistent with the SAR of related analogs. For example, analogs without the acid on the indole or removal of the indole acid headpiece leads to a ten-to hundred-fold decrease in affinity (data not shown).
Demonstration of mechanism-based activity
Programmed cell death can occur due to nonspecific cytotoxicity. Thus, it was imperative to prove that our compounds exhibit the mechanism-based activity expected for a Mcl-1 inhibitor [5, 20] . One piece of evidence to support this claim is if the compounds exhibit more potent cellular activity in cell lines that are Mcl-1 dependent compared to those that are not. To identify cell lines that were very sensitive to Mcl-1 inhibition, we searched the hematologic cancer cell lines profiled in the CCLE (Broad Institute) [41] that had a profile of protein expression that we had found earlier to predict Mcl-1 selective activity [42] . One of the most sensitive cell lines predicted from this analysis was NCI H929, a multiple myeloma (MM) cell line shown in previous studies to be Mcl-1 sensitive [20] . We also predicted that chronic myelogenous leukemia cell line K562 would be resistant to Mcl-1 inhibitors and could serve as an inactive control for off target toxicity. We used the NCI H929 cell line to test if our compounds acted like a BH3 mimetic and displaced Bim from Mcl-1 [13, 43] . As shown in Fig. 3 dosing cells with compounds 4 or 5 causes a near complete displacement of Bim from Mcl-1 when compared to the DMSO vehicle in a co-IP experiment. A similar dosedependent displacement of Noxa from Mcl-1 is shown in the Fig. S1 . These data show that the mechanistically expected displacement of Bim or Noxa from Mcl-1 is observed after compound dosing. Unexpectedly, we also observed that compound dosing with our Mcl-1 inhibitor causes an increase in total Mcl-1 protein. As shown in the Fig. S1 , the increase in Mcl-1 levels is as much as 1.5-fold more than the vehicle after dosing with 4. This was also observed in an earlier study and it was hypothesized to be due to compound displacement of Noxa, a BH3 protein involved in Mcl-1 turnover [20] . The compound selectivity for Mcl-1 over another family member, Bcl-xl, is shown in Fig. 3B . No decrease is seen in the Bcl-xl/Bim band, in fact, an increase in Bim bound to Bcl-xl is observed, presumably due to the displacement of Bim from Mcl-1.
We next used BH3 profiling experiments to monitor mitochondrial depolarization and cytochrome c release caused by BH3 peptides or our small molecule BH3 mimetic [30] . As shown in Fig. 4A , the NCI H929 cell line is not affected when exposed to HRK a Bcl-xl-selective peptide, or Bad a Bcl-xl and Bcl-2 peptide. However, mitochondrial depolarization was observed after addition of the Mcl-1-specific peptide MS-1 and to Bim, a pan proapoptotic peptide. When compound 4 and 5 were dosed in the NCI H929 cell line mitochondrial depolarization nearly equipotent to the MS-1 peptide, which is one of the best Mcl-1-specific probes, reported in the literature [29, 44] . In Fig. 4B we show that the K562 heme cell line is insensitive to MS-1 and most other BH3 peptides with only moderate activity to the pan Bcl-2 family inhibitor Bim. The K562 cell line is also much less sensitive to compound 4 and 5. However, some activity is observed at high concentrations which may indicate some additional non-BH3 mimetic activity. When compound 4 activity was compared to the Mcl-1-specific MS-1 peptide in a larger panel of MM and AML cancer cell lines we see parallel activity of compound 4 and MS-1 to cause cytochrome c release due to mitochondrial depolarization. The cell line activity of our compounds observed in the BH3 profiling experiments is also reflected in proliferation assays (Table 1) on NCI H929/K562 cells and in a larger panel of AML and MM cancer cell lines shown in Fig. 4D . In the NCI H929/K562 cells, we found that dosing cells with compound 4 or 5 resulted in low micromolar GI 50 in the MS-1-sensitive cell line (NCI H929) and a five to eightfold lower (i.e., GI 50 (K562)/GI 50 (H929)) GI 50 activity for the MS-1-insensitive line (K562). Looking at the larger set of cell lines, the overall correlation between cytochrome c release ( Fig. 4C ) and activity of compounds in a proliferation assay (4D) is good but not perfect (e.g., MV411) which likely reflects additional cell line-specific factors or some additional non-BH3 mimetic activity that influences how primed cell lines are for death. We also tested compounds in a caspase activation assay (supplemented with only 5% FBS to reduce plasma interference) and found rapid activation at low concentrations only in the NCI H929-sensitive cell line. The difference observed in the proliferation and caspase assays between a BH3 MS-1-sensitive andinsensitive cell line suggests that most of the observed cell killing of the compound in the proliferation assay is indeed due to on-target Mcl-1-mediated activity.
As another test for specific on-target activity, we tested compounds 4 and 5 in a panel of re-engineered cell lines. These cell lines were re-engineered BCR-ABL + B-ALL cells modified to only contain specific exogenous human Bcl-2 family proteins [31] . As previously reported, these cell lines are able to unambiguously demonstrate on-target activity for Bcl-2 family inhibitors. When these cell lines were dosed with compounds 4 (Fig. 5A) or 5 (Fig. 5B) , a clear separation was observed for the activity of the compounds against cell lines with different Bcl-2 family proteins, with Mcl-1 having the lowest observed EC 50 followed by its closest related family member BFL-1. Both compounds show two-to threefold less activity against the Bcl-2-and Bcl-xl-engineered lines, respectively. The compounds do exhibit some off target toxicity at high concentrations based on the killing of the DKO (double Bax, Bak knockout), TKO (triple Bax, Bak, Mcl-1 knockout) cell lines at high micromolar concentrations. As seen in Fig. 5 , the compounds have reasonable selectivity for tool compounds but they are not close to the specificity achieved by venetoclax, an approved BH3 mimetic, that targets Bcl-2.
We next expanded our testing to include MM and AML primary patient samples. In Fig. 6A , we show a co-IP experiment on a patient sample that indicates that the majority of Bim in these cells is sequestered by Mcl-1. The high level of sequestration of Bim by Mcl-1 in this patient sample is consistent with these cell lines being Mcl-1 dependent [32] . When this sample was dosed with compound 4 we observed Annexin V and propidium iodide-positive cells at low micromolar concentrations of compound (Fig. 6B) . In Fig. 6C , we show an AML patient sample dosed using compounds 4 and 5. The AML patient sample also had reduced viability at low micromolar concentrations of our compounds. These two studies show that these primary patient samples are also sensitive to our compounds. However, further characterization of the Mcl-1 dependency of the patient samples is needed to insure that the sensitivity is primarily due to an Mcl-1-based mechanism.
Discussion
We have described the discovery of picomolar Mcl-1 inhibitors. The activity of these compounds, in multiple experiments is consistent with apoptosis mediated by an Mcl-1 BH3 mimetic. The compounds caused mitochondrial depolarization at single-digit nM concentrations and caspase activation in sensitive cancer cell lines. When tested in engineered cell lines containing specific Bcl-2 family members, we found lower IC 50 and higher specificity for compounds 4 and 5 than was reported for earlier literature compounds [31] . We also showed that patient samples from MM and AML had a response to compound treatment at low micromolar concentrations. Much more potent Mcl-1 inhibitors could thus be expected to be useful therapeutic agents in these cancers. These results suggest that the Mcl-1 inhibitors described here will be useful as tool molecules to study the role of Mcl-1 in cancer and serve as useful starting points for the discovery of Mcl-1 inhibitors as therapeutic agents.
Supporting information
Additional Supporting Information may be found online in the supporting information tab for this article: Fig. S1 . Dose-dependent disruption of Mcl-1/Noxa in AMO-1 cells. Fig. S2 . Dose-response data from a 3-day cell viability studies using compound 4 and 5. Fig. S3 . Additional cell-based characterization of compounds. Doc. S1. Additional methods details. Table S1 . X-ray data collection and refinement statistics (molecular replacement).
